The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome.We use functional cookies on this website, which are essential to the operation of this website and are always on.If you miss a dose,